Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 4th Intercepting Blood Cancers (IBC) Workshop was held in Barcelona, Spain, on March 19-21, 2026. This workshop brought together leading experts to share insights into precursor conditions and early interventions in blood cancers. The IBC 2026 Workshop was supported by Regeneron (Gold), Johnson & Johnson (Silver), Sanofi (Silver), Pfizer (Bronze), and an educational grant from Pharmacosmos. Enduring content from the workshop is supported by AstraZeneca. Supporters have no influence over the production of the content.
View all videos
IBC 2026
The 4th Intercepting Blood Cancers (IBC) Workshop
19–21 March 2026 | Barcelona, Spain
The 4th Intercepting Blood Cancers (IBC) Workshop was held in Barcelona, Spain, on March 19-21, 2026. This workshop brought together leading experts to share insights into precursor conditions and early interventions in blood cancers. The IBC 2026 Workshop was supported by Regeneron (Gold), Johnson & Johnson (Silver), Sanofi (Silver), Pfizer (Bronze), and an educational grant from Pharmacosmos. Enduring content from the workshop is supported by AstraZeneca. Supporters have no influence over the production of the content.
View all videos
Keynote talks
Clonal hematopoiesis, MBL and risk of hematological malignancies:
Susan Slager Mayo Clinic, Rochester, MN, United States
Somatic mutation and selection in ageing tissues
Inigo Martincorena Wellcome Sanger Institute, Cambridge, United Kingdom
Plenary session 1: Classification
Genetically-driven immune microenvironment landscapes across myeloma subtypes
Romanos Sklavenitis-Pistofidis City of Hope National Medical Center, Duarte, CA, United States
Evolution of clonal hematopoiesis to myeloid malignancy
Kristina Kirschner Mayo Clinic, Rochester, MN, United States
Insights into myeloid cancer prevention from the identification of novel germline risk variants for clonal haematopoiesis
Siddhartha Kar University of Cambridge, Cambridge, United Kingdom
Plenary session 2: Early detection, screening & risk stratification
Detection of pre-malignant clones at population scale using an in vivo methylation barcode
Jamie Blundell University of Cambridge, Cambridge, United Kingdom
Immune remodeling by clonal hematopoiesis in adoptive cell therapy
Juan Rodríguez Hospital Clínic de Barcelona, Barcelona, Spain
Prognostication in CLL
Adalgisa Condoluci Institute of Oncology Research, Bellinzona, Switzerland
Beyond blood cancers: updates on MCED and early detection across cancers
Elizabeth O'Donnell Dana-Farber Cancer Institute, Boston, MA, United States
Plenary session 3: Clonal expansion
Spontaneous and under treatment pressure clonal evolution patterns in MM
Mehmet Samur Dana-Farber Cancer Institute, Boston, MA, United States
Plenary session 4: Designing pre-cursor clinical trials
Early intervention in low- and intermediate-risk SMM
Salomon Manier Lille Hospital University, Lille, France
Plenary session 5: Defining response criteria
Novel endpoints for MBL/early-stage asymptomatic CLL
Tait Shanafelt Stanford University, Stanford, CA, United States
Non-hematologic endpoints for CH trials
Zhuoer Xie Moffitt Cancer Center, Rochester, MN, United States
Defining new endpoints for SMM
Francesca Gay University of Turin, Turin, Italy
Plenary session 6: Latest from clinical studies I
DFV890 and MAS825 for inflammatory marker reduction in patients with coronary heart disease and CHIP
Alexander Bick Vanderbilt University Medical Center, Nashville, TN, United States
Beyond CHIP: CCRS predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma
Zhuoer Xie Moffitt Cancer Center, Rochester, MN, United States
Plenary session 7: Latest from clinical trials II
Olutasidenib for low-risk MDS and CCUS
Kelly Chien MD Anderson Cancer Center, Houston, TX, United States
Immunotherapy and Phase II studies in SMM and MGUS
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
Plenary session 8: Latest from clinical trials III
Ivosidenib in IDH1-mutated CCUS
Kelly Bolton Washington University in St. Louis, St. Louis, MO, United States
Observational studies in MGUS and SMM
Karthik Ramasamy Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Combining daratumumab and teclistamab for high-risk SMM
Ola Landgren Sylvester Comprehensive Cancer Center, Miami, FL, United States
Ongoing Phase III studies in MGUS/SMM
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Plenary session 9: Can we predict treatment response or treatment resistance?
Genomic mechanisms of response and resistance
Brian Walker Sylvester Comprehensive Cancer Center, Miami, FL, United States
Spatial proteomics to identify resistance to therapy
Kane Foster Dana-Farber Cancer Institute, Boston, MA, United States
Dynamic immune signatures of response in SMM
Francesco Corrado Dana-Farber Cancer Institute, Boston, MA, United States
Plenary session 10: Latest innovations
Digital pathology and AI in predicting progression
Joshua Lewis Brigham and Women's Hospital, Boston, MA, United States
GLP1/2 agonists for the prevention of disease progression
Elizabeth O'Donnell Dana-Farber Cancer Institute, Boston, MA, United States
SMM/MGUS/MM track
Updates and follow-up from the iStopMM study
Sigrun Thorsteinsdottir University of Iceland, Reykjavik, Iceland
Risk stratification in SMM – the IMWG 2/20/20 model
Efstathios Kastritis National and Kapodistrian University of Athens, Athens, Greece
Utilizing PANGEA for risk stratification of MGUS and SMM
Elias Mai Heidelberg University, Heidelberg, Baden-Württemberg, Germany
CTCs and immunological tools for assessing risk of disease progression
Bruno Paiva University of Navarra, Pamplona, Spain
Updates on the PROMISE study
Catherine Marinac Dana-Farber Cancer Institute, Boston, MA, United States
Biochemical progression as an endpoint
Tarek Mouheddine Dana-Farber Cancer Institute, Boston, MA, United States
Is MRD the best endpoint to incorporate in MGUS/SMM clinical trials?
Natalie Callander University of Wisconsin, Madison, WI, United States
Dietary intervention trial in MGUS/SMM – food for thought
Urvi Shah Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Early rescue intervention with DPd in high-risk SMM and LINKER-MGUS1 study – linvolseltamab for SMM and MGUS
Jesús San Miguel University of Navarra, Navarra, Spain
Should high-risk SMM be treated with single-agent daratumumab or with curative-intent combination therapy? Dara-monotherapy
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Should high-risk SMM be treated with single-agent daratumumab or with curative-intent combination therapy? Curative-intent combination therapy
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
CHIP/CCUS/myeloid track
DNA methylation as a prognostic biomarker for predicting DNMT3A and TET2 pre-disease progression
Alexander Bick Vanderbilt University Medical Center, Nashville, TN, United States
Challenges and opportunities in CCUS trials
Uma Borate Ohio State University, Columbus, OH, United States
CDK4/6 inhibition as a therapeutic strategy in CH
Kelly Bolton Washington University in St. Louis, St. Louis, MO, United States
Dietary intervention trial in CH – food for thought
Urvi Shah Memorial Sloan Kettering Cancer Center, New York City, NY, United States
MBL/CLL/lymphoma track
Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL
Livius Penter Charité - Universitätsmedizin Berlin, Berlin, Germany
The developmental trajectory of CLL derived from sibling stem cell donors of CLL patients
Hendrik Veelken Leiden University, Leiden, Netherlands
Early intervention strategies in early-stage CLL
Clemens Wendtner Afghanistan
Vitamin D supplementation as early intervention in CLL
Tamar Tadmor Bnai Zion Medical Center, Haifa, Israel
Complementary interventions for early CLL
Lindsey Roeker Mayo Clinic, Rochester, MN, United States
Which future in the design of early interventions in MBL/CLL?
Lydia Scarfò Università Vita-Salute San Raffaele, Milan, Italy
